PTC Therapeutics, Inc.

NasdaqGS:PTCT Stock Report

Market Cap: US$5.5b

PTC Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:PTCT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Mar 26SellUS$170,581Matthew KleinIndividual2,662US$64.08
18 Feb 26SellUS$213,698Mark BouldingIndividual3,081US$69.36
18 Feb 26SellUS$216,473Neil AlmsteadIndividual3,121US$69.36
18 Feb 26SellUS$209,398Eric PauwelsIndividual3,019US$69.36
18 Feb 26SellUS$207,525Pierre GravierIndividual2,992US$69.36
18 Feb 26SellUS$172,290Lee GoldenIndividual2,484US$69.36
18 Feb 26SellUS$172,984Christine UtterIndividual2,494US$69.36
18 Feb 26SellUS$511,253Matthew KleinIndividual7,371US$69.36
08 Jan 26SellUS$71,863Neil AlmsteadIndividual940US$76.45
08 Jan 26SellUS$98,315Mark BouldingIndividual1,286US$76.45
08 Jan 26SellUS$111,158Eric PauwelsIndividual1,454US$76.45
08 Jan 26SellUS$66,206Lee GoldenIndividual866US$76.45
08 Jan 26SellUS$192,195Matthew KleinIndividual2,514US$76.45
08 Jan 26SellUS$79,049Christine UtterIndividual1,034US$76.45
07 Jan 26SellUS$186,098Neil AlmsteadIndividual2,411US$77.48
07 Jan 26SellUS$242,417Eric PauwelsIndividual3,141US$77.48
07 Jan 26SellUS$152,855Lee GoldenIndividual1,982US$77.48
07 Jan 26SellUS$201,919Christine UtterIndividual2,616US$77.45
07 Jan 26SellUS$629,895Matthew KleinIndividual8,165US$77.48
07 Jan 26SellUS$250,268Mark BouldingIndividual3,242US$77.48
06 Jan 26SellUS$164,596Pierre GravierIndividual2,139US$76.95
30 Dec 25SellUS$619,941Matthew KleinIndividual8,089US$76.64
02 Dec 25SellUS$271,052Matthew KleinIndividual3,428US$79.07
28 Aug 25SellUS$83,600Allan JacobsonIndividual1,667US$50.15
05 Aug 25SellUS$555,636Matthew KleinIndividual10,739US$51.74
15 Jul 25SellUS$124,441Pierre GravierIndividual2,516US$49.46
22 Apr 25SellUS$136,656Matthew KleinIndividual2,804US$48.74
02 Apr 25SellUS$42,114Lee GoldenIndividual897US$46.95

Insider Trading Volume

Insider Buying: PTCT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of PTCT?
Owner TypeNumber of SharesOwnership Percentage
State or Government32,6340.0331%
Individual Insiders2,060,2822.09%
Hedge Funds7,746,4157.85%
Institutions88,843,31890%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 88.21% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.4%
BlackRock, Inc.
12,778,999US$845.1m79.2%0.01%
10.6%
The Vanguard Group, Inc.
8,803,203US$582.2m6.2%0.01%
9.36%
RTW Investments, LP
7,746,415US$512.3m0%5.71%
5.86%
Janus Henderson Group plc
4,851,332US$320.8m28.6%0.12%
5.08%
State Street Global Advisors, Inc.
4,206,126US$278.2m34.2%0.01%
5%
The Toronto-Dominion Bank
4,138,215US$273.7m0%0.31%
4.67%
Wellington Management Group LLP
3,867,380US$255.7m-21.4%0.04%
3.92%
Cowen Inc.
3,246,525US$214.7m0%19.6%
3.38%
Armistice Capital LLC
2,801,869US$185.3m-14.5%4.76%
2.44%
Geode Capital Management, LLC
2,016,062US$133.3m3.34%0.01%
2.11%
D. E. Shaw & Co., L.P.
1,744,991US$115.4m-19.8%0.1%
2.03%
FMR LLC
1,680,138US$111.1m4.26%0.01%
2%
Jefferies Financial Group Inc.
1,658,481US$109.7m4.66%0.99%
1.86%
Michael Schmertzler
1,537,193US$101.7m0%no data
1.81%
Tang Capital Management, LLC
1,500,000US$99.2m0%4.9%
1.55%
Franklin Resources, Inc.
1,282,435US$84.8m11.2%0.03%
1.39%
Citadel Advisors LLC
1,154,455US$76.3m-33.3%0.06%
1.37%
Driehaus Capital Management LLC
1,136,188US$75.1m0.39%0.38%
1.36%
Point72 Asset Management, L.P.
1,128,551US$74.6m-12%0.13%
1.32%
UBS Asset Management AG
1,096,551US$72.5m88.4%0.01%
1.21%
Hood River Capital Management LLC
1,003,075US$66.3m0.73%0.68%
1.18%
Pictet Asset Management Limited
978,957US$64.7m-30.5%0.05%
1.09%
Palo Alto Investors LP
903,916US$59.8m4.79%8.87%
1.08%
SG Americas Securities, LLC
894,461US$59.2m588%0.08%
1.04%
Bank of America Corporation
859,660US$56.8m-14.1%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/29 19:25
End of Day Share Price 2026/03/27 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PTC Therapeutics, Inc. is covered by 34 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke HerrmannBaird
Joel BeattyBaird
null nullBaird